US2021038743A1PendingUtilityA1

Methods for treating parkinson's disease

58
Assignee: KOREA ADVANCED INST SCI & TECHPriority: Apr 25, 2018Filed: Oct 23, 2020Published: Feb 11, 2021
Est. expiryApr 25, 2038(~11.7 yrs left)· nominal 20-yr term from priority
Inventors:Daesoo KimJeongjin KimYoungsoo KimMinju Jeong
C12N 2310/141C12N 2310/14C12N 2310/11A61K 48/005A61P 25/16A61N 5/062C12N 15/1138C12N 15/867A61N 2005/0662A61N 2005/0663A61K 48/0075C12N 15/8645C12N 5/0619C12N 15/113C07H 21/04C12N 15/861C12N 15/86C12N 2750/14143A01K 2217/075C07K 14/47A61N 5/0622
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for treating Parkinson's disease. According to this method, a halorhodopsin protein, a polynucleotide encoding the halorhodopsin protein or a vector containing the polynucleotide above is treated to ventrolateral thalamus (VL) or medial globus pallidus (GPm) neurons of a subject having Parkinson's disease, followed by illumination with green light or a T type Ca2+ channel blocker is treated to VL neurons of a subject having Parkinson's disease to inhibit rebound firing of VL neurons. By inhibiting rebound firing of VL neurons, Parkinson's disease can be treated or prevented.

Claims

exact text as granted — not AI-modified
1 . A method for treating Parkinson's disease, comprising inhibiting rebound firing of ventrolateral thalamus (VL) neurons, wherein the ventrolateral thalamus (VL) neurons of a subject having Parkinson's disease are exposed to a T-type Ca2+ channel blocker in order to inhibit rebound firing of VL neurons. 
     
     
         2 . The method for treating Parkinson's disease according to  claim 1 , wherein the T-type Ca2+ channel blocker is a CaV3.1 gene expression inhibitor. 
     
     
         3 . The method for treating Parkinson's disease according to  claim 2 , wherein the CaV3.1 gene comprises the nucleotide sequence represented by SEQ ID NO: 3. 
     
     
         4 . The method for treating Parkinson's disease according to  claim 2 , wherein the CaV3.1 gene expression inhibitor comprises siRNA, shRNA, or miRNA that can bind to the CaV3.1 gene mRNA complementarily. 
     
     
         5 . The method for treating Parkinson's disease according to  claim 4 , wherein the shRNA comprises the nucleotide sequence represented by SEQ ID NO: 4. 
     
     
         6 . The method for treating Parkinson's disease according to  claim 4 , wherein the siRNA, shRNA or miRNA is inserted in a vector. 
     
     
         7 . The method for treating Parkinson's disease according to  claim 6 , wherein the vector is a DNA vector, a plasmid DNA vector, or a recombinant viral vector. 
     
     
         8 . The method for treating Parkinson's disease according to  claim 7 , wherein the recombinant viral vector is a retrovirus, adenovirus, adeno-associated virus, or lentivirus vector.

Join the waitlist — get patent alerts

Track US2021038743A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.